-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎The content team editor of WuXi AppTec, outside of clinical trials, monitors the reactogenicity of the new crown vaccine, including local and systemic reactions, to help medical practitioners and the public understand more about the new crown vaccine.
In order to facilitate the rapid evaluation of the new crown vaccine, the US Centers for Disease Control and Prevention has established an active monitoring system called v-safe to collect real-time data on new crown vaccine vaccinators across the United States.
Based on this system, the Centers for Disease Control and Prevention recently published an important study in the Journal of the American Medical Association (JAMA), analyzing the local and systemic response data actively reported by 3.
64 million people after being vaccinated with the mRNA COVID-19 vaccine.
Screenshot source: JAMAv-safe's monitoring system is voluntarily registered by vaccinators, and online health surveys are completed regularly through mobile notification messages.
The time span covers the day of vaccination until 12 months after the last dose of vaccination.
From the day of each dose of vaccination (day 0) to day 7, subjects need to answer questions about local and systemic reactions (such as pain at the injection site, fatigue, headache) and whether there are adverse health events (such as receiving medical care) ).
Although the questions in the questionnaire do not include allergic reactions (allergic reactions) or severe allergic reactions (anaphylaxis), subjects are free to add input related experience after vaccination.
This analysis covers the local and systemic response data collected by the v-safe system from December 14, 2020 to February 28, 2021, and people reported within 7 days after being vaccinated with Pfizer/BioNTech and Moderna's new crown vaccines (Johnson & Johnson single dose The new crown vaccine was authorized by the US FDA for emergency use at the end of February, so it was not included in this analysis).
As of February 21, 2021, more than 46 million people have received at least one dose of mRNA for the new crown vaccine.
A total of 3.
644 million people participated in the monitoring survey of v-safe and conducted at least one health survey within 7 days after the first dose of vaccine; of these, 1.
92 million reported that they had received the second dose of vaccine and completed a health survey within 7 days of vaccination .
Image source: Data from millions of vaccinators participating in v-safe monitoring by 123RF shows that pain at the injection site is common after v-safe vaccination.
Common systemic reactions include fatigue, headache, myalgia, chills, fever and arthralgia.
Most vaccinators reported injection site reactions (first dose: 70.
0%; second dose: 75.
2%) or systemic reactions (first dose: 50.
0%; second dose: 69.
4%) within 7 days of vaccination.
After the first dose of the vaccine, the most commonly reported local and systemic reactions include: pain at the injection site (67.
8%), fatigue (30.
9%), headache (25.
9%), myalgia (19.
4%), and chills (8.
8%) ), fever (8.
6%) and joint pain (8.
7%).
For both mRNA vaccines, the reactogenicity after the second dose was significantly stronger, especially the incidence of systemic reactions was significantly higher, including pain at the injection site (72.
3%), fatigue (53.
9%), and headache (46.
7) %), myalgia (44.
0%), chills (31.
3%), fever (29.
5%) and joint pain (25.
6%).
▲Local and systemic reactions reported 0-7 days after vaccination of mRNA new crown vaccine (data source: reference [1]; table compilation: new medical perspectives) Among the two vaccines, Moderna new crown vaccine vaccinators reported more after vaccination Response, especially after the second dose of vaccination.
In general, for the two vaccines and different doses, the proportion of subjects who reported local and systemic reactions was the highest on the first day after vaccination, and related symptoms could be relieved in a short period of time.
By the seventh day, the proportion of reports had dropped significantly.
Further analysis of populations <65 years and ≥65 years of age showed that the difference in vaccine reactogenicity was consistent with the overall findings, but people ≥65 years of age reported fewer local and systemic reactions.
The research team pointed out in the paper that the frequency of reactions reported by these vaccinators in the real world is consistent with the results observed in clinical trials.
The limitation of the study is that vaccinators need to voluntarily join the monitoring system online via mobile phones, so less than 10% of vaccinators are covered.
Although local and systemic reactions can be expected and are usually short-lived, they may directly affect the public's perception of vaccination.
Providing the public with "expectations" of these reactions may reduce the potential anxiety caused by reactogenicity after vaccination.
Are there many allergic reactions to the new crown vaccine? JAMA publishes safety data on vaccination for over 60,000 people.
3 NEJM articles on the same day: The post-vaccination infection is a case.
The new crown vaccine is generally effective in reducing 92% of new crown infections and 94% of cases among medical staff.
NEJM published data reference materials for 600,000 people in Israel inoculated with Pfizer/BioNTech vaccine [1] Chapin-Bardales J, et al.
, (2021).
Reactogenicity Following Receipt of mRNA-Based COVID-19 Vaccines.
JAMA, DOI: 10.
1001/jama.
2021.
5374 Note: This article aims to introduce the progress of medical and health research, not a treatment plan recommendation.
If you need guidance on treatment plans, please go to a regular hospital for treatment.
In order to facilitate the rapid evaluation of the new crown vaccine, the US Centers for Disease Control and Prevention has established an active monitoring system called v-safe to collect real-time data on new crown vaccine vaccinators across the United States.
Based on this system, the Centers for Disease Control and Prevention recently published an important study in the Journal of the American Medical Association (JAMA), analyzing the local and systemic response data actively reported by 3.
64 million people after being vaccinated with the mRNA COVID-19 vaccine.
Screenshot source: JAMAv-safe's monitoring system is voluntarily registered by vaccinators, and online health surveys are completed regularly through mobile notification messages.
The time span covers the day of vaccination until 12 months after the last dose of vaccination.
From the day of each dose of vaccination (day 0) to day 7, subjects need to answer questions about local and systemic reactions (such as pain at the injection site, fatigue, headache) and whether there are adverse health events (such as receiving medical care) ).
Although the questions in the questionnaire do not include allergic reactions (allergic reactions) or severe allergic reactions (anaphylaxis), subjects are free to add input related experience after vaccination.
This analysis covers the local and systemic response data collected by the v-safe system from December 14, 2020 to February 28, 2021, and people reported within 7 days after being vaccinated with Pfizer/BioNTech and Moderna's new crown vaccines (Johnson & Johnson single dose The new crown vaccine was authorized by the US FDA for emergency use at the end of February, so it was not included in this analysis).
As of February 21, 2021, more than 46 million people have received at least one dose of mRNA for the new crown vaccine.
A total of 3.
644 million people participated in the monitoring survey of v-safe and conducted at least one health survey within 7 days after the first dose of vaccine; of these, 1.
92 million reported that they had received the second dose of vaccine and completed a health survey within 7 days of vaccination .
Image source: Data from millions of vaccinators participating in v-safe monitoring by 123RF shows that pain at the injection site is common after v-safe vaccination.
Common systemic reactions include fatigue, headache, myalgia, chills, fever and arthralgia.
Most vaccinators reported injection site reactions (first dose: 70.
0%; second dose: 75.
2%) or systemic reactions (first dose: 50.
0%; second dose: 69.
4%) within 7 days of vaccination.
After the first dose of the vaccine, the most commonly reported local and systemic reactions include: pain at the injection site (67.
8%), fatigue (30.
9%), headache (25.
9%), myalgia (19.
4%), and chills (8.
8%) ), fever (8.
6%) and joint pain (8.
7%).
For both mRNA vaccines, the reactogenicity after the second dose was significantly stronger, especially the incidence of systemic reactions was significantly higher, including pain at the injection site (72.
3%), fatigue (53.
9%), and headache (46.
7) %), myalgia (44.
0%), chills (31.
3%), fever (29.
5%) and joint pain (25.
6%).
▲Local and systemic reactions reported 0-7 days after vaccination of mRNA new crown vaccine (data source: reference [1]; table compilation: new medical perspectives) Among the two vaccines, Moderna new crown vaccine vaccinators reported more after vaccination Response, especially after the second dose of vaccination.
In general, for the two vaccines and different doses, the proportion of subjects who reported local and systemic reactions was the highest on the first day after vaccination, and related symptoms could be relieved in a short period of time.
By the seventh day, the proportion of reports had dropped significantly.
Further analysis of populations <65 years and ≥65 years of age showed that the difference in vaccine reactogenicity was consistent with the overall findings, but people ≥65 years of age reported fewer local and systemic reactions.
The research team pointed out in the paper that the frequency of reactions reported by these vaccinators in the real world is consistent with the results observed in clinical trials.
The limitation of the study is that vaccinators need to voluntarily join the monitoring system online via mobile phones, so less than 10% of vaccinators are covered.
Although local and systemic reactions can be expected and are usually short-lived, they may directly affect the public's perception of vaccination.
Providing the public with "expectations" of these reactions may reduce the potential anxiety caused by reactogenicity after vaccination.
Are there many allergic reactions to the new crown vaccine? JAMA publishes safety data on vaccination for over 60,000 people.
3 NEJM articles on the same day: The post-vaccination infection is a case.
The new crown vaccine is generally effective in reducing 92% of new crown infections and 94% of cases among medical staff.
NEJM published data reference materials for 600,000 people in Israel inoculated with Pfizer/BioNTech vaccine [1] Chapin-Bardales J, et al.
, (2021).
Reactogenicity Following Receipt of mRNA-Based COVID-19 Vaccines.
JAMA, DOI: 10.
1001/jama.
2021.
5374 Note: This article aims to introduce the progress of medical and health research, not a treatment plan recommendation.
If you need guidance on treatment plans, please go to a regular hospital for treatment.
